Primo Thera Co. Ltd. has divulged new interleukin-6 receptor subunit β (IL-6Rβ; gp130) inhibitors potentially useful for the treatment of autoimmune disease.
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of psychiatric and neurological disorders.
Recurium IP Holdings LLC has disclosed new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers potentially useful for the treatment of cancer.
Shanghai Zheye Biotechnology LLC has discovered new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have synthesized new GTPase KRAS G12C mutant inhibitors potentially useful for the treatment of cancer, autoimmune disorders and inflammatory disorders.
Monte Rosa Therapeutics AG has reported new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 G1/S-specific cyclin-E1 (CCNE1)/cereblon interaction inducers and CCNE1 degradation inducers potentially useful for the treatment of cancer.
Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.
Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis.
RSS